Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO defended the company’s decision to sue rival Eli Lilly over its weight-loss drug advertising. Source link
Tag: iShares U.S. Pharmaceuticals ETF
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn’t catching a break this year. Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed…